Myth: Content marketing is about going viral.
Reality: It's about trust compounding over years. Chasing spikes loses customers; consistency keeps them.
What's your real retention driver?
Here's the flip: myth: more content equals more growth. Reality: retention beats volume every time. One piece that keeps them coming back outperforms ten one-offs. Play the long game.
7 years in crypto and the chart still does the same dance. Down weeks shake paper hands, up weeks reward the patient. My spot bag stays packed, 5m candles can scream all they want. Wagmi, lfg.
Robinhood’s biggest opportunity imo is capturing the next generation of investors
> younger users are increasingly trading through mobile apps
> crypto gives $HOOD a strong entry point into that audience
> RWAs + tokenized stocks can expand that onchain strategy
> legacy brokerages have large existing customer bases, while Robinhood has more room to compete for younger users
if more financial activity moves onchain, $HOOD is in an interesting position to capture that shift
bitcoin ordinals volume quietly hit new highs this week.
inscriptions are turning block space into a real fee market again.
miners finally have a second income stream that isn't just subsidies.
Bullish! GameFi charts now track sink-to-source ratios, not just token price.
Real economies burn more than they mint each epoch.
Watch the net emission line, not the hype.
90% of drug candidates fail in trials. Faster AI discovery just floods a bottleneck that can't scale. Quote: They promise speed but validation stays slow.
AI is accelerating drug discovery. But the pressure is shifting downstream, toward the work required to validate what discovery produces.
Across science and life sciences, AI is moving deeper into discovery. Anthropic is expanding AI into scientific research, Isomorphic Labs is scaling AI-first drug design and development, and Discovery Loop is building systems to automate experimental loops.
As these capabilities advance, more targets can be explored, more molecules can be designed, and more potential candidates can be generated. The discovery layer is becoming faster and more expansive.
But accelerating discovery does not automatically accelerate the path to validation.
A promising candidate still has to be evaluated, tested, and supported by sufficient evidence before it can move forward. Clinical validation is where this downstream pressure becomes especially visible. The gains from faster discovery can begin to narrow if the path to validation remains slow and difficult to scale.
For Life AI, this raises a critical question: How do we make sure the path to validation can keep pace as AI accelerates discovery?
Oil at $100 is a lagging signal, not a leading one. The real risk is an overbought rejection that snaps yields higher and hits equities harder than any supply gain justifies.
Oil is knocking on $100 again. 👀
Brent is pushing toward $97–99.
WTI is holding around $91–94.
Supply concerns are back on the tape, putting oil back in focus across macro markets.
Higher oil prices are feeding into inflation expectations and yields, adding pressure to risk assets.
$100 Brent is the key level to watch.
Does oil have enough momentum to break higher or are we due for a rejection? 👇